## V T Farewell

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11186127/publications.pdf

Version: 2024-02-01

136950 330143 6,177 41 32 37 citations h-index g-index papers 41 41 41 5853 citing authors docs citations times ranked all docs

#	Article	IF	CITATIONS
1	Methods for assessing responsiveness. Journal of Clinical Epidemiology, 2000, 53, 459-468.	5.0	1,224
2	The Use of Mixture Models for the Analysis of Survival Data with Long-Term Survivors. Biometrics, 1982, 38, 1041.	1.4	592
3	Human factors and cardiac surgery: A multicenter study. Journal of Thoracic and Cardiovascular Surgery, 2000, 119, 661-672.	0.8	455
4	Monitoring surgical performance using risk-adjusted cumulative sum charts. Biostatistics, 2000, 1, 441-452.	1.5	371
5	Mortality studies in psoriatic arthritis. Results from a single outpatient clinic. I. Causes and risk of death. Arthritis and Rheumatism, 1997, 40, 1868-1872.	6.7	315
6	Health-related quality of life of patients with psoriatic arthritis: A comparison with patients with rheumatoid arthritis. Arthritis and Rheumatism, 2001, 45, 151-158.	6.7	302
7	Mortality studies in psoriatic arthritis: Results from a single outpatient center. II. Prognostic indicators for death. Arthritis and Rheumatism, 1998, 41, 1103-1110.	6.7	283
8	Use of risk-adjusted CUSUM and RSPRTcharts for monitoring in medical contexts. Statistical Methods in Medical Research, 2003, 12, 147-170.	1.5	255
9	Cardiovascular morbidity in psoriatic arthritis. Annals of the Rheumatic Diseases, 2009, 68, 1131-1135.	0.9	253
10	Protective Environment for Marrow Transplant Recipients. Annals of Internal Medicine, 1978, 89, 893.	3.9	197
11	The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients. Rheumatology, 2011, 50, 982-988.	1.9	155
12	Clinical indicators of progression in psoriatic arthritis: multivariate relative risk model. Journal of Rheumatology, 1995, 22, 675-9.	2.0	134
13	Validating the SF-36 health survey questionnaire in patients with psoriatic arthritis. Journal of Rheumatology, 1997, 24, 511-7.	2.0	133
14	Predictors for radiological damage in psoriatic arthritis: results from a single centre. Annals of the Rheumatic Diseases, 2007, 66, 370-376.	0.9	131
15	The role of hla antigens as indicators of disease progression in psoriatic arthritis. Arthritis and Rheumatism, 1995, 38, 845-850.	6.7	112
16	Some results on the estimation of logistic models based on retrospective data. Biometrika, 1979, 66, 27-32.	2.4	98
17	A Markov model for HIV disease progression including the effect of HIV diagnosis and treatment: Application to AIDS prediction in England and Wales. , 1997, 16, 2191-2210.		90
18	High-dose combination chemotherapy for acute nonlymphoblastic leukemia in adults. Cancer, 1981, 48, 1073-1081.	4.1	87

#	Article	IF	Citations
19	Occurrence and correlates of fatigue in psoriatic arthritis. Annals of the Rheumatic Diseases, 2009, 68, 1553-1558.	0.9	77
20	Two-Part and Related Regression Models for Longitudinal Data. Annual Review of Statistics and Its Application, 2017, 4, 283-315.	7.0	75
21	Clinical and radiological damage in psoriatic arthritis. Annals of the Rheumatic Diseases, 2006, 65, 478-481.	0.9	73
22	The combined effect of breast cancer risk factors. Cancer, 1977, 40, 931-936.	4.1	72
23	Kidney Biopsy in Systemic Lupus Erythematosus. II. Survival Analyses According to Biopsy Results. Arthritis and Rheumatism, 1991, 34, 1268-1273.	6.7	72
24	HLA markers and progression in psoriatic arthritis. Journal of Rheumatology, 1998, 25, 730-3.	2.0	72
25	Kidney biopsy in systemic lupus erythematosus. Arthritis and Rheumatism, 1994, 37, 559-567.	6.7	62
26	Progression in psoriatic arthritis: role of time varying clinical indicators. Journal of Rheumatology, 1999, 26, 2409-13.	2.0	58
27	Monitoring paired binary surgical outcomes using cumulative sum charts. , 1999, 18, 69-86.		53
28	Responsiveness of health status instruments to changes in articular status and perceived health in patients with psoriatic arthritis. Journal of Rheumatology, 1998, 25, 2146-55.	2.0	51
29	A Pearson-type goodness-of-fit test for stationary and time-continuous Markov regression models. Statistics in Medicine, 2002, 21, 1899-1911.	1.6	45
30	A risk-adjusted Sets method for monitoring adverse medical outcomes. Statistics in Medicine, 2004, 23, 1593-1602.	1.6	45
31	New therapy explains the fall in AIDS incidence with a substantial rise in number of persons on treatment expected. Aids, 1999, 13, 103-108.	2.2	40
32	Intensification therapy for acute nonlymphoblastic leukemia in adults. Cancer, 1983, 52, 198-205.	4.1	38
33	Using serial observations to identify predictors of progression to aids in the Toronto Sexual Contact Study. Journal of Clinical Epidemiology, 1992, 45, 245-253.	5.0	36
34	SARS incubation and quarantine times: when is an exposed individual known to be disease free?. Statistics in Medicine, 2005, 24, 3431-3445.	1.6	34
35	Relative Risk and Odds Ratio Regression. Annual Review of Public Health, 1986, 7, 35-58.	17.4	24
36	Dynamic modelling in a study of surgical error management. Statistics in Medicine, 2007, 26, 5189-5202.	1.6	22

## V T FAREWELL

#	Article	IF	CITATIONS
37	Relationship of the Arthritis Impact Measurement Scales to changes in articular status and functional performance in patients with psoriatic arthritis. Journal of Rheumatology, 1996, 23, 1932-7.	2.0	19
38	Biostatistical issues and concepts in epidemiologic research. Journal of Chronic Diseases, 1986, 39, 1169-1183.	1.2	16
39	Followup in psoriatic arthritis: relationship to disease characteristics. Journal of Rheumatology, 1992, 19, 917-20.	2.0	6
40	A Bayesian dynamic model for influenza surveillance. Statistics in Medicine, 2006, 25, 1819-1820.	1.6	0
41	Commentary on â€~Measurement in clinical trials: A neglected issue for statisticians?'. Statistics in Medicine, 2009, 28, 3210-3212.	1.6	0